List of Contributions

With CDRHs initiative to reclassify high risk class III IVDs to Class II, interested to hear feedback on impact of this initiative in the context of gene therapy trials where companion diagnostics (CDx) have required concurrent approvals with your BLAs and via PMA route (in majority of gene therapy trials). ...